AA
BCRX icon

AlphaCentric Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

AlphaCentric Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-675,000
Closed -$4.17M – 232
2024
Q2 		$4.17M Hold
675,000
– – 3.07% 2
2024
Q1 		$3.43M Hold
675,000
– – 2.07% 6
2023
Q4 		$4.04M Buy
675,000
+26,000
+4% +$151K 2.71% 3
2023
Q3 		$4.59M Buy
649,000
+79,000
+14% +$568K 2.61% 3
2023
Q2 		$4.01M Buy
570,000
+150,500
+36% +$1.21M 2.23% 5
2023
Q1 		$3.5M Buy
419,500
+294,500
+236% +$2.84M 2.41% 4
2022
Q4 		$1.44M Buy
125,000
+55,000
+79% +$686K 1.42% 15
2022
Q3 		$882K Buy
+70,000
New +$901K 0.91% 32
2021
Q4 		$242K Buy
+17,500
New +$232K 0.07% 91

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

AlphaCentric Advisors's BCRX Position: Q3 2024 in Review

AlphaCentric Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2024, closing a stake of 675,000 shares — an estimated $4.17M sold.

AlphaCentric Advisors first reported a position in BCRX in Q4 2021 and held it in 9 quarters. The position peaked at $4.59M in Q3 2023. 257 funds tracked by Wall St. Rank hold BCRX as of Q3 2024.

  • AlphaCentric Advisors reported no remaining BioCryst Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 675,000 BioCryst Pharmaceuticals shares in Q3 2024, an estimated $4.17M.
  • AlphaCentric Advisors first reported a position in BioCryst Pharmaceuticals in Q4 2021 and held it in 9 quarters.
  • AlphaCentric Advisors's BioCryst Pharmaceuticals position peaked at $4.59M in Q3 2023.
  • 257 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2024.

Based on AlphaCentric Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.